AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34050027 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive serum transfer from immunized mice; dosage: not specified; duration: not specified.
Number of subjects: 0
Study 34050027 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with liposome system containing 10 recombinant surface antigens; dosage: 5 ng individual antigen; duration: not specified.
Number of subjects: 0
Study 34050027 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization in ferrets; dosage: not specified; duration: not specified.
Number of subjects: 0
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonal keratometries on areas surrounding the maximum curvature point
Number of subjects: 743
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Steepest front keratometry
Number of subjects: 743
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Front best-fit sphere
Number of subjects: 743
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean keratometry of both surfaces
Number of subjects: 743
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Belin-Ambrósio Deviation
Number of subjects: 743
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Index height decentration
Number of subjects: 743
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: LOGIK (platform-independent)
Number of subjects: 743
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum radius in both surfaces
Number of subjects: 743
Study 34050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum pachymetry (PachyMin)
Number of subjects: 743
Study 34050156 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated genetic/epigenetic analysis method for liquid biopsy
Number of subjects: 126
Study 34050156 — intervention group
Group type: EXPERIMENTAL
Intervention: LIQUORICE algorithm for detecting circulating tumor DNA
Number of subjects: 126
Study 34050156 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated machine learning classifier for liquid biopsy analysis
Number of subjects: 126
Study 34050156 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA fragmentation patterns
Number of subjects: 126
Study 34050237 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine diphosphate (TDP) concentrations on post-operative day 1
Number of subjects: 35
Study 34050237 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte transketolase activity (ETKA) on post-operative day 1
Number of subjects: 35
Study 34050237 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum magnesium concentrations on post-operative day 1
Number of subjects: 35
Study 34050237 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative serum magnesium concentrations
Number of subjects: 35
Study 34050260 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (10 mg/kg weekly for 4 weeks, then every other week) with pomalidomide and dexamethasone (Pd)
Number of subjects: 47
Study 34050368 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methods (random forests, artificial neural networks, support vector machines)
Number of subjects: 2229
Study 34050368 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methods (random forests)
Number of subjects: 2229
Study 34050402 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity tracker with personalized text message feedback
Number of subjects: 30
Study 34050897 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance group (decision tree followed)
Number of subjects: 0
Study 34050897 — intervention group
Group type: COMPARATOR
Intervention: Non-compliance group (decision tree not followed)
Number of subjects: 0
Study 34050897 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance group
Number of subjects: 0
Study 34050897 — intervention group
Group type: COMPARATOR
Intervention: Non-compliance group
Number of subjects: 0
Study 34050897 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance group (baseline HbA1c ≥ 7%)
Number of subjects: 0
Study 34050897 — intervention group
Group type: COMPARATOR
Intervention: Non-compliance group (baseline HbA1c ≥ 7%)
Number of subjects: 0
Study 34051135 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA closure
Number of subjects: 816
Study 34051147 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe COVID-19
Number of subjects: 0
Study 34051147 — intervention group
Group type: COMPARATOR
Intervention: Non-SARS-CoV-2 pneumonia
Number of subjects: 0
Study 34051147 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating NKT cell frequency
Number of subjects: 0
Study 34051169 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34051177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months
Number of subjects: 101
Study 34051329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously every 2 weeks until unacceptable toxicity or disease progression
Number of subjects: 49
Study 34051732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg)
Number of subjects: 1356
Study 34051732 — intervention group
Group type: COMPARATOR
Intervention: Non-ipilimumab therapy
Number of subjects: 1356
Study 34051732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg) and Non-ipilimumab therapy
Number of subjects: 1356
Study 34051772 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Young Children program (8-week duration)
Number of subjects: 60
Study 34051772 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Young Children program
Number of subjects: 60
Study 34051830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity assessment in complex interventions
Number of subjects: 0
Study 34051829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause including a sugar-containing drink
Number of subjects: 17
Study 34051829 — intervention group
Group type: COMPARATOR
Intervention: Control (no pause or drink)
Number of subjects: 17
Study 34051936 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 1051
Study 34051936 — intervention group
Group type: COMPARATOR
Intervention: Follow-up from baseline to year 18
Number of subjects: 1051
Study 34051936 — intervention group
Group type: EXPERIMENTAL
Intervention: Better management of glycaemia and blood pressure levels
Number of subjects: 1051
Study 34052189 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular (RV) involvement in TTS
Number of subjects: 839
Study 34052189 — intervention group
Group type: COMPARATOR
Intervention: No RV involvement in TTS
Number of subjects: 839
Study 34052189 — intervention group
Group type: EXPERIMENTAL
Intervention: RV involvement in TTS
Number of subjects: 839
Study 34052202 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 80
Study 34052255 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 34052655 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS 8-item scales
Number of subjects: 648
Study 34052655 — intervention group
Group type: COMPARATOR
Intervention: PHQ-9
Number of subjects: 648
Study 34052655 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS 8-item scales and PHQ-9
Number of subjects: 648
Study 34052655 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS scales (4-item, 6-item, 8-item)
Number of subjects: 648
Study 34052655 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS scales and PHQ-9
Number of subjects: 648
Study 34052705 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib 30 mg BID (DL1)
Number of subjects: 13
Study 34052705 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib 45 mg BID (DL2)
Number of subjects: 13
Study 34052705 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib plus carboplatin and pemetrexed
Number of subjects: 13
Study 34052929 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, carboplatin and veliparib
Number of subjects: 15
Study 34053461 — intervention group
Group type: EXPERIMENTAL
Intervention: Public involvement consultation exercise
Number of subjects: 10
Study 34053461 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of scientific, ethical, humanitarian, and economic basis for the project
Number of subjects: 10
Study 34053461 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment options discussion
Number of subjects: 10
Study 34053461 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive thematic analysis
Number of subjects: 10
Study 34053461 — intervention group
Group type: EXPERIMENTAL
Intervention: Public trust in scientific rigour
Number of subjects: 10
Study 34053700 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 300 mg BID with food
Number of subjects: 35
Study 34053700 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg BID with food
Number of subjects: 35
Study 34053788 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34053923 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 5
Study 34054076 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOLs (Group A: 18 unilateral, Group B: 14 bilateral)
Number of subjects: 43
Study 34054076 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOLs (Group C: 12 unilateral, Group D: 12 bilateral)
Number of subjects: 43
Study 34054076 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOLs (Group B)
Number of subjects: 43
Study 34054076 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOLs (Group D)
Number of subjects: 43
Study 34054076 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOLs
Number of subjects: 43
Study 34054076 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 43
Study 34054076 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOLs and Monofocal IOLs
Number of subjects: 43
Study 34054569 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil (specific phosphodiesterase-5 inhibitor)
Number of subjects: 22
Study 34055086 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administration of paclitaxel (70 mg/m2) with modulated electro-hyperthermia
Number of subjects: 12
Study 34055086 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administration of cisplatin with modulated electro-hyperthermia
Number of subjects: 12
Study 34055403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group with SBP target of <120 mm Hg
Number of subjects: 9361
Study 34055403 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group with SBP target of <140 mm Hg
Number of subjects: 9361
Study 34055657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 12
Study 34055836 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34055928 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting Oral Anticoagulant Therapy
Number of subjects: 0
Study 34056067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (details not available)
Number of subjects: 0
Study 34056067 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not available)
Number of subjects: 0
Study 34046552 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary rehabilitation programme
Number of subjects: 0
Study 34056607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg Q2W until disease progression, unacceptable toxicity, or trial withdrawal
Number of subjects: 35
Study 34056607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg Q2W
Number of subjects: 35
Study 34056687 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for advanced NSCLC (specific treatment details not available)
Number of subjects: 42
Study 34056870 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical debridement, antibiotic, and hyperbaric oxygen therapy over a 6-month period
Number of subjects: 2
Study 34056870 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2
Study 34056892 — intervention group
Group type: EXPERIMENTAL
Intervention: iVascular Luminor™ drug-coated balloon (DCB) and Angiolite™ drug-eluting stent
Number of subjects: 50
Study 34056913 — intervention group
Group type: EXPERIMENTAL
Intervention: New-Onset Perioperative Atrial Fibrillation (POAF)
Number of subjects: 4624
Study 34056913 — intervention group
Group type: COMPARATOR
Intervention: No New-Onset Perioperative Atrial Fibrillation (POAF)
Number of subjects: 4624
Study 34057232 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T (axicabtagene-ciloleucel; tisagenlecleucel)
Number of subjects: 0
Study 34057424 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer game-based rehabilitation program (GRP) for 16 weeks
Number of subjects: 60
Study 34057424 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for 16 weeks
Number of subjects: 60
Study 34057734 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV training for healthcare providers (HCPs)
Number of subjects: 1662
Study 34057820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 346
Study 34058027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (25 mg, increased to 50 mg if tolerated)
Number of subjects: 86
Study 34058148 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased MUC5AC concentrations
Number of subjects: 331
Study 34058148 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC5AC concentration
Number of subjects: 331
Study 34058148 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC5AC concentrations
Number of subjects: 331
Study 34058148 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC5AC
Number of subjects: 331
Study 34058148 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC5AC-producing pathways
Number of subjects: 331
Study 34058856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP) measurement
Number of subjects: 0
Study 34058888 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose solution
Number of subjects: 17
Study 34058888 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 17
Study 34059026 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone to renin ratio (ARR) > 10 (ng/dL)/(mU/L) after confirmatory test
Number of subjects: 141
Study 34059026 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal vein sampling (AVS)
Number of subjects: 141
Study 34059046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia
Number of subjects: 286
Study 34059046 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, bilateral procedure, ASA level, postoperative hypothermia
Number of subjects: 286
Study 34059046 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypothermia
Number of subjects: 286
Study 34059074 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted, family volunteers delivered, parents' skills training intervention
Number of subjects: 540
Study 34059074 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 540
Study 34059127 — intervention group
Group type: EXPERIMENTAL
Intervention: LDA model
Number of subjects: 434
Study 34059127 — intervention group
Group type: EXPERIMENTAL
Intervention: RF model
Number of subjects: 434
Study 34059127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Scheimpflug tonometry
Number of subjects: 434
Study 34059148 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Champions (trained volunteers providing support)
Number of subjects: 120
Study 34059148 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 120
Study 34059276 — intervention group
Group type: EXPERIMENTAL
Intervention: Test strip (15% w/w calcium sodium phosphosilicate)
Number of subjects: 120
Study 34059276 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study 34059276 — intervention group
Group type: EXPERIMENTAL
Intervention: Test strip
Number of subjects: 120
Study 34059384 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased EAT attenuation (EAT-At), a marker of EAT inflammation
Number of subjects: 192
Study 34059384 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 192
Study 34059384 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT volume
Number of subjects: 192
Study 34059525 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 308
Study 34059525 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 308
Study 34059525 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 308
Study 34059556 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI imaging and muscle enzyme values (creatine phosphokinase and aldolase)
Number of subjects: 27
Study 34059639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosciclopirox (CPX-POM) administered intraperitoneally at doses of 235 mg/kg and 470 mg/kg for four weeks
Number of subjects: 0
Study 34059639 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34059786 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 63
Study 34059786 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of leptin
Number of subjects: 63
Study 34059786 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of adiponectin
Number of subjects: 63
Study 34059786 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels
Number of subjects: 63
Study 34059786 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipokine levels
Number of subjects: 63
Study 34059801 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 104
Study 34059991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF), median duration of dosing 74 weeks
Number of subjects: 500
Study 34059991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Number of subjects: 500
Study 34059995 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass and fundoplication
Number of subjects: 0
Study 34059995 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34060012 — intervention group
Group type: EXPERIMENTAL
Intervention: NTK 120 mg once every 2 weeks (NTK Q2W)
Number of subjects: 213
Study 34060012 — intervention group
Group type: EXPERIMENTAL
Intervention: NTK 120 mg once every 4 weeks (NTK Q4W)
Number of subjects: 213
Study 34060012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 34060434 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Aphasia Rapid Test (ART)
Number of subjects: 30
Study 34060440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic grader pathway
Number of subjects: 553
Study 34060440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic grader pathway (seven-field Early Treatment Diabetic Retinopathy Study)
Number of subjects: 553
Study 34060440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic grader pathway (ultra-wide field imaging)
Number of subjects: 553
Study 34060483 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic pharmacological blockade of activin A using soluble activin receptor type IIB ligand trap
Number of subjects: 0
Study 34060483 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-specific adeno-associated virus-mediated downregulation of its receptor ACVR2A/B
Number of subjects: 0
Study 34060704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation discontinuation (≥7 consecutive days)
Number of subjects: 23882
Study 34060705 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Of the Dying Evaluation (i-CODE) questionnaire
Number of subjects: 914
Study 34060714 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective beta-blockers (NSBB) administered intravenously
Number of subjects: 52
Study 34060714 — intervention group
Group type: EXPERIMENTAL
Intervention: MR elastography of the liver or spleen
Number of subjects: 52
Study 34060926 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-based approach to modify step length asymmetry in 15 individuals with marked asymmetry.
Number of subjects: 36
Study 34060926 — intervention group
Group type: COMPARATOR
Intervention: Walking without biofeedback.
Number of subjects: 36
Study 34060926 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking more symmetrically (post-biofeedback).
Number of subjects: 36
Study 34061040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic physical activity intervention for 12 weeks
Number of subjects: 20
Study 34061040 — intervention group
Group type: COMPARATOR
Intervention: Delayed control condition
Number of subjects: 20
Study 34061040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic physical activity intervention
Number of subjects: 20
Study 34061122 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed educational intervention (video summarizing inpatient management guidelines)
Number of subjects: 91
Study 34061122 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91
Study 34061299 — intervention group
Group type: EXPERIMENTAL
Intervention: iMTA Productivity Cost Questionnaire (iPCQ)
Number of subjects: 144
Study 34061352 — intervention group
Group type: COMPARATOR
Intervention: Suction aspiration after cervical preparation
Number of subjects: 17795
Study 34061352 — intervention group
Group type: COMPARATOR
Intervention: Dilatation and curettage
Number of subjects: 17795
Study 34061352 — intervention group
Group type: COMPARATOR
Intervention: Suction aspiration
Number of subjects: 17795
Study 34061352 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone plus misoprostol
Number of subjects: 17795
Study 34061352 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 17795
Study 34061581 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 34061581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34061621 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedonic hunger assessment
Number of subjects: 0
Study 34061621 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating assessment
Number of subjects: 0